Catalent completed the acquisition biologics development and manufacturing facility of Vaccine Manufacturing and Innovation Centre.

Catalent, a company which provides integrated services, delivery technologies and manufacturing solutions to develop and launch pharmaceuticals, biologics and consumer health, completed the acquisition biologics development and manufacturing facility of Vaccine Manufacturing and Innovation Centre, a pharmaceutical company. Financial terms were not disclosed. “This acquisition allows Catalent to collaborate with the rich academic and biomedical science community centered around Oxford, with its world-class talent, and will result in a facility that provides opportunities to transform innovation into real treatments for patients across the United Kingdom, Europe, and beyond. Our priority is to complete construction as soon as possible to be able to commence customer programs in 2022. We will then integrate its capabilities within our existing network of biologics facilities across Europe to offer a flexible range of manufacturing, technology, and development solutions for the pipeline of thousands of development programs currently underway,” Mike Riley, Catalent President.